WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Xiaobin Wu Biography and Net Worth

COO of BeiGene

Xiaobin Wu, Ph.D., joined BeiGene in 2018 and currently serves as President, Chief Operating Officer, and General Manager of China. Dr. Wu was previously the Country Manager of Pfizer China and the Regional President of Pfizer Essential Health for Greater China from October 2009 to April 2018. Under Dr. Wu’s leadership, Pfizer expanded its portfolio and organization, grew sales meaningfully, initiated a range of innovative marketing programs, and established its position as a leading multinational pharmaceutical company in China. Prior to Pfizer, Dr. Wu served as President and Managing Director of Wyeth China and Hong Kong from August 2004 to October 2009. Before Wyeth, Dr. Wu was General Manager of Bayer Healthcare in China from 2001 to 2004. He started his career in 1992 in sales and marketing with Bayer in Germany. Dr. Wu received a Ph.D. in Biochemistry and Pharmacology and a master’s degree in Molecular Biology from the University of Konstanz in Germany.

What is Xiaobin Wu's net worth?: The estimated net worth of Xiaobin Wu is at least $794,250.00 as of September 17th, 2024. Dr. Wu owns 4,500 shares of BeiGene stock worth more than $794,250 as of December 21st. This net worth evaluation does not reflect any other investments that Dr. Wu may own. Additionally, Dr. Wu receives a salary of $1,690,000.00 as COO at BeiGene. Learn More about Xiaobin Wu's net worth.
How old is Xiaobin Wu?: Dr. Wu is currently 62 years old. There are 3 older executives and no younger executives at BeiGene. Learn More on Xiaobin Wu's age.
What is Xiaobin Wu's salary?: As the COO of BeiGene, Ltd., Dr. Wu earns $1,690,000.00 per year. The highest earning executive at BeiGene is Mr. John V. Oyler, Founder, Executive Chairman & CEO, who commands a salary of $2,050,000.00 per year. Learn More on Xiaobin Wu's salary.
How do I contact Xiaobin Wu?: The corporate mailing address for Dr. Wu and other BeiGene executives is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. BeiGene can also be reached via phone at (345) 949-4123 and via email at [email protected]. Learn More on Xiaobin Wu's contact information.
Has Xiaobin Wu been buying or selling shares of BeiGene?: Xiaobin Wu has not been actively trading shares of BeiGene during the last quarter. Most recently, Xiaobin Wu sold 4,500 shares of the business's stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $200.14, for a transaction totalling $900,630.00. Learn More on Xiaobin Wu's trading history.
Who are BeiGene's active insiders?: BeiGene's insider roster includes Timothy Chen (Director), Donald Glazer (Director), Jane Huang (CMO), Chan Lee (SVP), Howard Liang (CFO), John Oyler (Founder, Executive Chairman & CEO), Corazon (Corsee) Sanders (Director), Julia Wang (CFO), Lai Wang (Insider), Xiaodong Wang (Insider), and Xiaobin Wu (COO). Learn More on BeiGene's active insiders.
Are insiders buying or selling shares of BeiGene?: During the last twelve months, insiders at the sold shares 19 times. They sold a total of 1,214,613 shares worth more than $226,013,519.58. The most recent insider tranaction occured on December, 10th when insider Xiaodong Wang sold 41,760 shares worth more than $7,804,944.00. Insiders at BeiGene own 7.4% of the company. Learn More about insider trades at BeiGene.
Information on this page was last updated on 12/10/2024.

Xiaobin Wu Insider Trading History at BeiGene

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/19/2024	Sell	4,500	$200.14	$900,630.00
9/17/2024	Sell	500	$200.00	$100,000.00	4,500
9/3/2024	Sell	5,556	$189.65	$1,053,695.40
6/24/2024	Sell	1,459	$159.79	$233,133.61
6/26/2023	Sell	1,495	$182.37	$272,643.15
6/7/2023	Sell	3,291	$224.73	$739,586.43
5/8/2023	Sell	7,000	$253.72	$1,776,040.00
6/21/2022	Sell	1,010	$144.36	$145,803.60
6/17/2022	Sell	578	$139.60	$80,688.80	1,010
6/6/2022	Sell	3,410	$141.99	$484,185.90
5/5/2022	Sell	6,725	$164.35	$1,105,253.75
7/6/2021	Sell	10,180	$325.53	$3,313,895.40	1,081,389
6/18/2021	Sell	1,156	$330.93	$382,555.08
6/7/2021	Sell	3,398	$352.54	$1,197,930.92	1,150,757
5/3/2021	Sell	6,715	$343.00	$2,303,245.00
7/20/2020	Sell	3,300	$249.22	$822,426.00	1,423,562
7/17/2020	Sell	700	$245.74	$172,018.00	1,423,562
7/15/2020	Sell	2,700	$241.11	$650,997.00	1,466,462
7/13/2020	Sell	3,000	$220.00	$660,000.00	1,466,462
6/8/2020	Sell	2,800	$170.83	$478,324.00	1,380,415
5/1/2020	Sell	7,024	$141.33	$992,701.92
5/1/2019	Sell	5,955	$124.52	$741,516.60

Xiaobin Wu Buying and Selling Activity at BeiGene

BeiGene Company Overview

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Today's Range

Now: $176.50

$175.80

$179.25

50 Day Range

MA: $200.99

$174.72

$227.05

2 Week Range

Now: $176.50

$126.97

$248.16

Volume

337,011 shs

Average Volume

284,766 shs

Market Capitalization

$17.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57

WARNING: “Buffett Indicator” flashing for first time in 50 years

From Behind the Markets | Ad

Take these 4 steps today to protect your retirement NOW

Xiaobin Wu Biography and Net Worth

What is Xiaobin Wu's net worth?

How old is Xiaobin Wu?

What is Xiaobin Wu's salary?

How do I contact Xiaobin Wu?

Has Xiaobin Wu been buying or selling shares of BeiGene?

Who are BeiGene's active insiders?

Are insiders buying or selling shares of BeiGene?